Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies

Show simple item record

dc.contributor.author Ehlert, Katerina
dc.contributor.author Heinze, Birgit
dc.contributor.author Graham, Marien Alet
dc.contributor.author Swanepoel, De Wet
dc.date.accessioned 2023-02-22T12:58:02Z
dc.date.available 2023-02-22T12:58:02Z
dc.date.issued 2023-01
dc.description.abstract OBJECTIVE : This study investigated mobile health enabled surveillance in ototoxicity. METHOD : This was a longitudinal study of 32 participants receiving chemotherapy. Baseline and exit audiograms that included conventional and extended high frequency audiometry were recorded within the patient's treatment venue using a validated mobile health audiometer. RESULTS : Average hearing thresholds at baseline were within the normal range (81.2 per cent left; 93.8 per cent right), reducing at exit testing (71.9 per cent left; 78.1 per cent right). Half of participants presented with a threshold shift according to ototoxicity monitoring criteria. The frequencies affected the most were between 4000 and 16 000 Hz, with left ears significantly more affected than right ears. Noise levels exceeded the maximum permissible ambient noise levels in up to 43.8 per cent of low frequencies (250–1000 Hz). CONCLUSION : Mobile health supported audiometry proved to be an efficacious tool for ototoxicity monitoring at the treatment venue. Changes in hearing ability over time could be tracked, improving surveillance in patients with full treatment schedules. en_US
dc.description.department Science, Mathematics and Technology Education en_US
dc.description.department Speech-Language Pathology and Audiology en_US
dc.description.librarian hj2023 en_US
dc.description.uri https://www.cambridge.org/core/journals/journal-of-laryngology-and-otology en_US
dc.identifier.citation Ehlert, K., Heinze, B., Graham, M., & Swanepoel, D. (2023). Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies. The Journal of Laryngology & Otology, 137(1), 61-67. doi: 10.1017/S0022215122001281. en_US
dc.identifier.issn 0022-2151 (print)
dc.identifier.issn 1748-5460 (online)
dc.identifier.other 10.1017/S0022215122001281
dc.identifier.uri https://repository.up.ac.za/handle/2263/89768
dc.language.iso en en_US
dc.publisher Cambridge University Press en_US
dc.rights © The Author(s), 2022. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/). en_US
dc.subject Chemotherapy agent en_US
dc.subject Cancer en_US
dc.subject Carboplatin en_US
dc.subject Cisplatin en_US
dc.subject Oxaliplatin en_US
dc.subject Hearing disorder en_US
dc.subject Ototoxicity en_US
dc.subject Drug induced en_US
dc.title Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record